Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;35:209-213

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Retraction (v40,p566)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gelband, C. H.
Right arrow Articles by Raizada, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gelband, C. H.
Right arrow Articles by Raizada, M. K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
*POTASSIUM CHLORIDE
Medline Plus Health Information
*Genes and Gene Therapy
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Gene therapy

(Hypertension. 2000;35:209.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Angiotensin I–Converting Enzyme Antisense Prevents Altered Renal Vascular Reactivity, but Not High Blood Pressure, in Spontaneously Hypertensive Rats

Craig H. Gelband; Hongwei Wang; Monica L. Gardon; Kimberley Keene; Drew S. Goldberg; Phyllis Y. Reaves; Michael J. Katovich; Mohan K. Raizada

From the Department of Physiology, University of Florida College of Medicine (C.H.G., H.W., M.L.G., K.K., D.S.G., P.Y.R., M.K.R.); the Department of Pharmacodynamics, University of Florida College of Pharmacy (M.J.K.); and the University of Florida Brain Institute (M.K.R.), Gainesville, Fla.

Correspondence to Craig H. Gelband, PhD, Department of Physiology, University of Florida College of Medicine, PO Box 100274, Gainesville, FL 32610. E-mail Gelband{at}phys.med.ufl.edu

Abstract—The renin-angiotensin system plays a critical role in the control of blood pressure, and its hyperactivity is associated with the development of human primary hypertension. Because low-dose angiotensin I–converting enzyme (ACE) inhibitors cause small reductions in blood pressure that are associated with the complete reversal of altered vascular pathophysiology, our objective in this study was to determine whether ACE antisense (ACE-AS) gene delivery prevents alterations in renal vascular physiology in the parents and F1 offspring of AS-treated spontaneously hypertensive rats (SHR). A single bolus intracardiac injection of ACE-AS (2x108 colony-forming units) in SHR neonates caused a modest (18±3 mm Hg, n=7 to 9) lowering of blood pressure, which was maintained in the F1 generation offspring (n=7 to 9). Alterations in renal vascular reactivity, electrophysiology, and [Ca2+]i homeostasis are underlying mechanisms associated with the development and establishment of hypertension. Renal resistance arterioles from truncated ACE sense–treated SHR showed a significantly enhanced contractile response to KCl and phenylephrine (n=24 rings from 6 animals, P<0.01) and significantly attenuated acetylcholine-induced relaxations (n=24 rings from 6 animals, P<0.01) compared with arterioles from ACE-AS–treated SHR. In addition, compared with cells dissociated from arterioles of ACE-AS–treated SHR, cells from truncated ACE sense–treated animal vessels had a resting membrane potential that was 22±4 mV more depolarized (n=38, P<0.01), an enhanced L-type Ca2+ current density (2.2±0.3 versus 1.2±0.2 pA/pF, n=23, P<0.01), a decreased Kv current density (16.2±1.3 versus 5.4±2.2 pA/pF, n=34, P<0.01), and increased Ang II–dependent changes in [Ca2+]i (n=142, P<0.01). Similar effects of ACE-AS treatment were observed in the F1 offspring. These results demonstrate that ACE-AS permanently prevents alterations in renal vascular pathophysiology in spite of the modest effect that ACE-AS had on high blood pressure in SHR.


Key Words: hypertension, renal • calcium channels • potassium channels • arterioles • gene therapy




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
N. Mihailovic-Stanojevic, D. Jovovic, Z. Miloradovic, J. Grujic-Milanovic, M. Jerkic, and J. Markovic-Lipkovski
Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan
Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1142 - 1150.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. Khurana, J. F. Martin, and I. Zachary
Gene Therapy for Cardiovascular Disease: A Case for Cautious Optimism
Hypertension, November 1, 2001; 38(5): 1210 - 1216.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. H. Gelband, M. J. Katovich, and M. K. Raizada
Current Perspectives on the Use of Gene Therapy for Hypertension
Circ. Res., December 8, 2000; 87(12): 1118 - 1122.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. Gardon, M. K Raizada, M. J Katovich, K. H Berecek, and C. H Gelband
Gene therapy for hypertension and restenosis
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 211 - 216.
[PDF]